Instil Bio, Inc. (TIL) Stock Price & Analysis
Instil Bio, Inc. (TIL) rose 0.00% to USD 7.13 as of July 25, 2026 at 04:48 UTC, according to Nexqual real-time market data.
TIL last closed at USD 7.13; the session ranged USD 7.13–7.25 on volume of 10,584 shares. Market capitalization is —, with a 52-week range of USD 5.67–33.83 (NCM). Source: Nexqual, July 25, 2026 at 04:48 UTC.
Key Statistics (as of July 25, 2026 at 04:48 UTC)
| Price | USD 7.13 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 7.13 |
| Open | USD 7.13 |
| Day Range | USD 7.13 – 7.25 |
| 52-Week Range | USD 5.67 – 33.83 |
| Volume | 10,584 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (TIL)
Nexqual's technical model rates TIL "SELL" based on 2 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 04:48 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 25.27 (oversold) |
| vs SMA50 | Below (USD 7.78) |
| MACD | -0.16 (negative) |
From Instil Bio, Inc.'s Latest SEC 10-K Filing (filed 2026-03-27)
Key Strengths & Strategy (as disclosed to the SEC)
- Any marketing application for a drug or biologic submitted to the FDA for approval, including a product candidate with a Fast Track designation and/or breakthrough therapy designation, may be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval.
- Prior to developing AXN-2510, our development efforts were focused on pursuing the development of cell therapies, including our proprietary folate receptor alpha co-stimulatory antigen receptor (CoStAR) tumor infiltrating lymphocyte (TIL) cell therapy for the treatment of cancer.
- We believe that our approach, strategy and experience provide us with certain competitive advantages.
Partnerships
- The license and collaboration agreement with ImmuneOnco was terminated in January 2026.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| HOWL | Werewolf Therapeutics, Inc. | USD 0.43 | ▲ 16.99% |
| DSGN | Design Therapeutics, Inc. | USD 11.78 | ▲ 0% |
| LYEL | Lyell Immunopharma, Inc. | USD 12.63 | ▼ 1.64% |
| FTH | Faeth Therapeutics, Inc. | USD 28.29 | ▼ 1.29% |
| ANNX | Annexon, Inc. | USD 5.22 | ▼ 0.19% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 04:48 UTC. This page is informational and not investment advice.